Literature DB >> 12003986

Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.

Katsunori Yanagihara1, Kazunori Tomono, Yoshifumi Imamura, Yukihiro Kaneko, Misuzu Kuroki, Toyomitsu Sawai, Yoshitsugu Miyazaki, Yoichi Hirakata, Hiroshi Mukae, Jun-Ichi Kadota, Shigeru Kohno.   

Abstract

Fourteen-membered macrolides (e.g. clarithromycin and erythromycin), but not 16-membered macrolides (e.g. josamycin), are effective in diffuse panbronchiolitis. However, there are no studies that have compared the effects of 14- and 16-membered macrolide antibiotics on biofilm formation. Treatment with high-dose clarithromycin (100 mg/kg) resulted in a significant decrease in the number of viable bacteria in an experimental murine model. Josamycin at a dose of up to 100 mg/kg had no effect on the number of viable bacteria in the lung. Our results may explain, at least in part, the clinical efficacy of 14-membered macrolide antibiotics in patients with chronic pneumonia caused by Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003986     DOI: 10.1093/jac/dkf013

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Macrolide immunomodulation of chronic respiratory diseases.

Authors:  Daniel P Healy
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

2.  Safety and tolerability of clarithromycin administered to children at higher-than-recommended doses.

Authors:  D A Kafetzis; F Chantzi; G Tigani; C L Skevaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

3.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 4.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa.

Authors:  Thilo Köhler; Jean-Luc Dumas; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

6.  Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Nobuko Araki; Koichi Yamada; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

7.  Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa.

Authors:  Julia Gödeke; Christian Pustelny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

Review 8.  Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

Authors:  Paul King
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms.

Authors:  Stephanie J Cole; Angela R Records; Mona W Orr; Sara B Linden; Vincent T Lee
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.